Articles About NYSE:NVS
March 07, 2014
Novartis' blood cancer drug Jakavi met its primary endpoint in a late-stage clinical trial evaluating the drug in patients with a rare bone marrow disease.
March 04, 2014
Novartis stock has been on a strong run, but is now pulling back.
March 03, 2014
Novartis chair Joerg Reinhardt has denied speculation into a possible merger between Novartis and its Swiss competitor Roche.
February 26, 2014
Novartis joins competitors in a clinical trial data transparency effort that would allow medical researchers access to patient-level data of new medicines.
February 23, 2014
The Tokyo offices of Novartis' Japanese unit was raided by prosecutors on Wednesday following allegations that the company manipulated data.
February 18, 2014
Novartis stock has been on a strong run and is now trading near all-time high prices.
February 17, 2014
Novartis has acquired CoStim Pharmaceuticals for an undisclosed amount in a move that will likely help the company compete with rival immunotherapy programs.
February 03, 2014
Novartis will cut as many as 4,000 jobs as part of a restructuring plan that reallocates resources for planned product launches and other new growth areas.
January 26, 2014
Novartis was denied approval by the European Medicines Agency for its breakthrough drug, serelaxin (marketed as Reasanz), which treats acute heart failure.
January 24, 2014
When releasing earnings last October, Novartis noted that the hit to earnings the release of the generic version of Diovan would come in 2014.
January 18, 2014
Novartis has run into another research roadblock for its cancer drug Tasigna after employees of the company's Japanese unit breached the study's protocol.
January 10, 2014
Novartis and Merck are looking to trade businesses as both companies hope to bulk up their core strength areas and shed other lines of business.